Document Detail


Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults.
MedLine Citation:
PMID:  11269678     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Cyclosporin A (CsA) in combination with corticosteroids can be used effectively in steroid-sensitive nephrotic syndrome. However, reports documenting the effectiveness ofCsA monotherapy against such a condition have been scarce. In 11 adults with minimal-change nephrotic syndrome, we have tried very low-dose CsA in the hope of inducing remission without using either corticosteroid or any other immunosuppressive drugs. PATIENTS AND METHODS: Indications for treatment included steroid-sensitive relapsing nephrotic syndrome (7 patients) and first-episode nephrotic syndrome (4 patients). In all patients, corticosteroid and cytotoxic agents had not been given before entry. CsA was administered orally at an initial dose of 2.4 (range 1.5 - 3.1) mg/kg per day. RESULTS: Analysis of the clinical course revealed that 8 of 11 patients entered complete remission after a mean duration of 44 +/- 31 days, whereas 3 patients failed to enter remission to CsA alone, resulting in complete remission combined with methylprednisolone pulse therapy without conventional oral prednisolone. CsA dosages and trough levels between responders and non-responders were similar. Non-responders had much higher levels of serum total cholesterol and higher daily urinary excretion of protein than those of responders, respectively. No patients had significant decrease in creatinine clearance, development of hypertension or suffered from other CsA associated serious side-effects. CONCLUSION: The present data suggest that CsA monotherapy at a very low dose could induce complete remission in adult patients with minimal-change nephrotic syndrome. Conversely, severe hypercholesterolemia would be likely to inhibit the action of CsA against nephrotic conditions.
Authors:
H Matsumoto; T Nakao; T Okada; Y Nagaoka; T Shino; M Yoshino; H Hidaka
Related Documents :
20847568 - Accelerated decline of gfr in diabetic nephropathy predicted by interferon release assa...
19910748 - Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobu...
6310828 - A case of fabry's disease.
9820448 - Epstein-barr virus detection in kidney biopsy specimens correlates with glomerular mesa...
12175828 - Reconstruction of the temporomandibular joint autogenous compared with alloplastic.
8909828 - Overgrowth of enterococcus faecium in the feces of patients with hematologic malignancies.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  55     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-03-27     Completed Date:  2001-06-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  143-8     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Tokyo Medical University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cyclosporine / therapeutic use*
Female
Humans
Hypercholesterolemia / complications
Immunosuppressive Agents / therapeutic use*
Japan
Male
Middle Aged
Nephrotic Syndrome / drug therapy*
Prospective Studies
Remission Induction
Statistics, Nonparametric
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Re-evaluating criteria for peritoneal dialysis in "classical" (D+) hemolytic uremic syndrome.
Next Document:  Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.